PB 58 of 2025
National Health (Highly Specialised Drugs Program) Special Arrangement Amendment (June Update) Instrument 2025
National Health Act 1953
I, REBECCA RICHARDSON, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, Disability and Ageing, delegate of the Minister for Health and Ageing, make this Instrument under subsection 100(2) of the National Health Act 1953.
Dated 29 May 2025
REBECCA RICHARDSON
Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division
2 Commencement
3 Authority
4 Schedules
Schedule 1—Amendments
National Health (Highly Specialised Drugs Program) Special Arrangement 2021
(PB 27 of 2021) 2
Commencement information | ||
Column 1 | Column 2 | Column 3 |
Provisions | Commencement | Date/Details |
1. The whole of this instrument | 1 June 2025 | 1 June 2025 |
Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.
This instrument is made under subsection 100(2) of the National Health Act 1953.
Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.
|
|
| Adalicip | C12120 C14061 C14063 C14064 C14107 C14136 |
| See Schedule 2 | See Schedule 2 |
|
|
| Azacitidine‑Teva | C12439 C12983 C12986 C13010 C13011 C13012 C13015 C13029 |
| See Schedule 2 | See Schedule 2 |
|
|
| Cyclosporin Sandoz | C6631 C6638 C6643 C6660 C9694 C9695 C9742 C9764 C15360 C15361 |
| 120 | 5 |